User menu

Epratuzumab (anti-CD22 mAb targeting b-cells) provides clinically meaningful reductions in corticosteroid (CS) use with a favorable safety profile in patients with Moderate/Severe flaring SLE: Results from Randomized controlled trials (RCTs)

Bibliographic reference Wallace, Daniel J. ; Houssiau, Frédéric ; Hobbs, Kathryn ; Strand, Vibeke ; Tak, Paul-Peter ; et. al. Epratuzumab (anti-CD22 mAb targeting b-cells) provides clinically meaningful reductions in corticosteroid (CS) use with a favorable safety profile in patients with Moderate/Severe flaring SLE: Results from Randomized controlled trials (RCTs).72nd Annual Scientific Meeting of the American-College-of-Rheumatology/43rd Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals (San Francisco (Ca), Oct 24-29, 2008). In: Arthritis & Rheumatism, Vol. 58, no. 9, p. S571-S572 (2008)
Permanent URL http://hdl.handle.net/2078.1/59159
  1. Zhang, Arthritis Rheum, 56, 4132 (2007)
  2. Lander, Lupus, 11, 340 (2002)
  3. Petri, Arthritis Rheum, 54, S446 (2006)
  4. Bombardier, Arthritis Rheum, 35, 630 (1992)